The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 5, 2011, Pages 1246-1257

  Brewer Jr , H Bryan ^a,b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b Washington Cardiovascular Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ANACETRAPIB; APOLIPOPROTEIN A1; ATORVASTATIN; DALCETRAPIB; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; NICOTINIC ACID; TORCETRAPIB; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL SPECIFICITY; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CORONARY ARTERY ATHEROSCLEROSIS; DIET RESTRICTION; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; EXERCISE; FLUSHING; HUMAN; HYDROLYSIS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOKING CESSATION; SYSTEMATIC REVIEW; ANIMAL; ATHEROSCLEROSIS; BLOOD; METABOLISM; RISK;

ANIMALIA;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; LIPOPROTEINS, HDL; RISK;

EID: 79955653216     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0163     Document Type: Review

References (117)

1. Castelli WP, Anderson K, Wilson PW, Levy D 1992 Lipids and risk of coronary heart disease: the Framingham study. Ann Epidemiol 2:23-28
2. Gordon DJ, Rifkind BM 1989 High-density lipoprotein: the clinical implications of recent studies. N Engl J Med 321:1311-1316 (Pubitemid 19267219)
3. Scandinavian Simvastatin Survival Study Group 1994 Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1350-1351
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E 1996 The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009 (Pubitemid 26338729)
6. Heart Protection Study Collaborative Group 2002 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360:7-22
7. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK 2005 Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435 (Pubitemid 40471450)
8. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R 2005 Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278
9. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207
10. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC Treating to New Targets Investigators 2007 HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular disease. N Engl J Med 357:1301-1310
11. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, Blechacz B, Bassler D, Wei X, Sharman A, Whitt I, Alves da Silva S, Khalid Z, Nordmann AJ, Zhou Q, Walter SD, Vale N, Bhatnagar N, O'Regan C, Mills EJ, Bucher HC, Montori VM, Guyatt GH 2009 Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338:b92
12. Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJ 2010 HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. JUPITER Trial Study Group. Lancet 376:333-339
13. Badimon JJ, Badimon L, Fuster V 1990 Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85:1234-1241
14. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM 1991 Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353:265-267 (Pubitemid 21896769)
15. Plump AS, Scott CJ, Breslow JL 1994 Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 91:9607-9611 (Pubitemid 24297964)
16. Hoeg JM, Santamarina-Fojo S, Bérard AM, Cornhill JF, Herderick EE, Feldman SH, Haudenschild CC, Vaisman BL, Hoyt Jr RF, Demosky Jr SJ, Kauffman RD, Hazel CM, Marcovina SM, Brewer Jr HB 1996 Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 93:11448-11453 (Pubitemid 26347141)
17. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W 1986 Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8:1245-1255 (Pubitemid 17208898)
18. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, DowdyAA,Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ 2001 Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592 (Pubitemid 33126837)
19. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R 2003 Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290:2292-2300 (Pubitemid 37430562)
20. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE 2007 Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297:499-508 (Pubitemid 46220805)
21. Taylor AJ, Lee HJ, Sullenberger LE 2006 The effect of 24 months of combination statin and extended-release niacin on carotid intima- media thickness: ARBITER 3. Curr Med Res Opin 22:2243-2250 (Pubitemid 44789989)
22. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, Griffen L, Taylor AJ 2010 The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 55:2721-2726
23. Brown BG, Stukovsky KH, Zhao XQ 2006 Simultaneous lowdensity lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 17:631-636 (Pubitemid 44729955)
24. Glomset JA 1970 Physiological role of lecithin-cholesterol acyltransferase. Am J Clin Nutr 23:1129-1136
25. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest Jr J, Hayden MR 1999 Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22:336-345 (Pubitemid 29369523)
26. Bodzioch M, Orsó E, Klucken J, Langmann T, Böttcher A, Diederich W, Drobnik W, Barlage S, Büchler C, Porsch-Ozcürümez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G 1999 The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22: 347-351 (Pubitemid 29369524)
27. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denèfle P, Assmann G 1999 Tangier disease is caused by mutations in the ATP binding cassette transporter 1 (ABC1) gene. Nat Genet 22:352-355 (Pubitemid 29369525)
28. Remaley AT, Rust S, Rosier M, Knapper C, Naudin L, Broccardo C, Peterson KM, Koch C, Arnould I, Prades C, Duverger N, Funke H, Assman G, Dinger M, Dean M, Chimini G, Santamarina-Fojo S, Fredrickson DS, Denefle P, Brewer Jr HB 1999 Human ATPbinding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc Natl Acad Sci USA 96:12685-12690 (Pubitemid 29513563)
29. Brousseau ME, Schaefer EJ, Dupuis J, Eustace B, Van Eerdewegh P, Goldkamp AL, Thurston LM, FitzGerald MG, Yasek-McKenna D, O'Neill G, Eberhart GP, Weiffenbach B, Ordovas JM, Freeman MW, Brown Jr RH, Gu JZ 2000 Novel mutations in the gene encoding ATP-binding cassette 1 in four Tangier disease kindreds. J Lipid Res 41:433-441
30. Lawn RM, Wade DP, Garvin MR,Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF 1999 The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 104:R25-R31 (Pubitemid 29536327)
31. Santamarina-Fojo S, Peterson K, Knapper C, Qiu Y, Freeman L, Cheng JF, Osorio J, Remaley A, Yang XP, Haudenschild C, Prades C, Chimini G, Blackmon E, Francois T, Duverger N, Rubin EM, Rosier M, Denèfle P, Fredrickson DS, Brewer Jr HB 2000 Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter. Proc Natl Acad Sci USA 97:7987-7992 (Pubitemid 30460760)
32. Castro GR, Fielding CJ 1988 Early incorporation of cell-derived cholesterol into pre-β-migrating high-density lipoprotein. Biochemistry 27:25-29 (Pubitemid 18036281)
33. Oram JF, Vaughan AM 2000 ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Curr Opin Lipidol 11:253-260 (Pubitemid 30336022)
34. Neufeld EB, Stonik JA, Demosky Jr SJ, Knapper CL, Combs CA, Cooney A,ComlyM,DwyerN, Blanchette-Mackie J, RemaleyAT, Santamarina-Fojo S, Brewer Jr HB 2004 The ABCA1 transporter modulates late endocytic trafficking: insights from the correction of the genetic defect in Tangier disease. J Biol Chem 279:15571-15578 (Pubitemid 38618958)
35. Remaley AT, Stonik JA, Demosky SJ, Neufeld EB, Bocharov AV, Vishnyakova TG, Eggerman TL, Patterson AP, Duverger NJ, Santamarina- Fojo S, Brewer Jr HB 2001 Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter. Biochem Biophys Res Commun 280:818-823
36. Liu L, Bortnick AE, Nickel M, Dhanasekaran P, Subbaiah PV, Lund-Katz S, Rothblat GH, Phillips MC 2003 Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles. J BiolChem278:42976-42984 (Pubitemid 37345910)
37. Wang N, Lan D, Chen W, Matsuura F, Tall AR 2004 ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 101:9774-9779
38. Kennedy MA, Barrera GC, Nakamura K, Baldán A, Tarr P, Fishbein MC, Frank J, Francone OL, Edwards PA 2005 ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 1:121-131 (Pubitemid 43977167)
39. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR 2006 HDL from CETP-deficient subjects show enhanced ability to promote cholesterol efflux from macrophages in an apoE-and ABCG1-dependent pathway. J Clin Invest 116:1435-1442
40. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, RothblatGH2003 Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23: 712-719
41. Williams DL, Connelly MA, Temel RE, Swarnakar S, Phillips MC, de la Llera-Moya M, Rothblat GH 1999 Scavenger receptor B1 and cholesterol trafficking. Curr Opin Lipidol 10:329-339
42. Duong M, Collins HL, Jin W, Zanotti I, Favari E, Rothblat GH 2006 Relative contribution of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. Arterioscler Thromb Vasc Biol 26:541-547
43. Van Eck M, Bos IS, Hildebrand RB, Van Rij BT, Van Berkel TJ 2004 Dual role for scavenger receptor class B, type I on bone marrow- derived cells in atherosclerotic lesion development. Am J Pathol 165:785-794 (Pubitemid 39129286)
44. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P 2000 Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR α. Proc Natl Acad Sci USA 97:12097-12102
45. Schwartz K, Lawn RM, Wade DP 2000 ABC1 gene expression and apoA-I-mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun 274:794-802 (Pubitemid 30663699)
46. Costet P, Luo Y, Wang N, Tall AR 2000 Sterol-dependent transactivation of the ABC1 promoter by the liverXreceptor/retinoidX receptor. J Biol Chem 275:28240-28245
47. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P 2001 A PPAR γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171
48. Wang N, Ranalletta M, Matsuura F, Peng F, Tall AR 2006 LXRinduced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler Thromb Vasc Biol 26:1310-1316 (Pubitemid 44305375)
49. Schwartz CC, Vlahcevic ZR, Halloran LG, Swell L 1981 An in vivo evaluation in man of the transfer of esterified cholesterol between lipoproteins and into the liver and bile. Biochim Biophys Acta 663: 143-162 (Pubitemid 11169824)
50. Shamburek RD, Vanden Broek JM, Cooper PS, Brewer Jr HB, Schwartz CC 2003 Cholesteryl ester output to tissues directly from HDL is minimal in humans. Circulation 108:IV-133 (Abstract)
51. TallAR1993 Plasma cholesteryl ester transfer protein. J Lipid Res 34:1255-1274
52. Chapman MJ, Le Goff W, Guerin M, Kontush A 2010 Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 31:149-164
53. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M 1996 Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271:518-520
54. Trigatti BL, Krieger M, Rigotti A 2003 Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 23:1732-1738 (Pubitemid 37254855)
55. Santamarina-Fojo S, Haudenschild C, Amar M 1998 The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 9:211-219 (Pubitemid 28274350)
56. Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C 2001 The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 155:269-281 (Pubitemid 32209296)
57. Jahangiri A, Rader DJ, Marchadier D, Curtiss LK, Bonnet DJ, Rye KA 2005 Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J Lipid Res 46:896-903
58. Rye KA, Clay MA, Barter PJ 1999 Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 145:227-238 (Pubitemid 29359129)
59. Haghpassand M, Bourassa PA, Francone OL, Aiello RJ 2001 Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J Clin Invest 108:1315-1320 (Pubitemid 33107759)
60. Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD, Cain WJ, Fruchart-Najib J, Neufeld ED, Remaley AT, Brewer Jr HB, Santamarina-Fojo S 2001 ABCA1 overexpression leads to hyperalphalipoproteinemia. J Clin Invest 108:303-309
61. Wellington CL, Brunham LR, Zhou S, Singaraja RR, Visscher H, Gelfer A, Ross C, James E, Liu G, Huber MT, Yang YZ, Parks RJ, Groen A, Fruchart-Najib J, Hayden MR 2003 Alterations of plasma lipids in mice via adenoviral-mediated hepatic over-expression of human ABCA1. J Lipid Res 44:1470-1480 (Pubitemid 37279591)
62. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS 2005 Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115:1333-1342 (Pubitemid 40629053)
63. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR 2006 Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 116:1052-1062
64. Barter PJ, Baker PW, Rye KA 2002 Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 13:285-288
65. Dimayuga P, Zhu J, Oguchi S, Chyu KY, Xu XO, Yano J, Shah PK, Nilsson J, Cercek B 1999 Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun 264:465-468 (Pubitemid 29516109)
66. Nicholls SJ, Cutri B, Worthley SG, Kee P, Rye KA, Bao S, Barter PJ 2005 Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 25:2416-2421 (Pubitemid 41552664)
67. Mackness MI, Arrol S, Abbott C, Durrington PN 1993 Protection of low-density lipoprotein against oxidative modification by highdensity lipoprotein associated paraoxonase. Atherosclerosis 104: 129-135 (Pubitemid 24035640)
68. Marathe GK, Zimmerman GA, McIntyre TM 2003 Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem 278:3937-3947 (Pubitemid 36801125)
69. Sugano M, Tsuchida K, Makino N 2000 High-density lipoproteins protect endothelial cells from tumor necrosis factor-α-induced apoptosis. Biochem Biophys Res Commun 272:872-876
70. Mineo C, Deguchi H, Griffin JH, Shaul PW 2006 Endothelial and antithrombotic actions of HDL. Circ Res 98:1352-1364 (Pubitemid 43948059)
71. Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ 2006 High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 26:1144-1149 (Pubitemid 43732125)
72. Rodríguez C, González-Díez M, Badimon L, Martínez-González J 2009 Sphingosine-1-phosphate: a bioactive lipid that confers highdensity lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost 101:665-673
73. Nofer JR, Brodde MF, Kehrel BE 2010 High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol 37:726-735
74. Toth PP 2010 Activation of intracellular signaling systems by highdensity lipoproteins. J Clin Lipidol 4:376-381
75. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW 2007 Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest 117:746-756 (Pubitemid 46348533)
76. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schäfers M, Herrgott I, Mersmann J, Larmann J, Hermann S, Stypmann J, Schober O, Hildebrand R, Schulz R, Heusch G, Haude M, von Wnuck Lipinski K, Herzog C, Schmitz M, Erbel R, Chun J, Levkau B 2006 High-density lipoproteins and their constituent, sphingosine-1- phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 114:1403-1409 (Pubitemid 44454560)
77. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM 2001 A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 42:1308-1317 (Pubitemid 32744255)
78. Ansell BJ 2007 Targeting the anti-inflammatory effects of highdensity lipoprotein. Am J Cardiol 100:n3-9
79. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM 2009 The role of dysfunctional HDL in atherosclerosis. J Lipid Res 50:S145-S149
80. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, Mueller M, Horváth T, Doerries C, Heinemann M, Flemmer S, Markowski A, Manes C, Bahr MJ, Haller H, von Eckardstein A, Drexler H, Landmesser U 2010 Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extendedrelease niacin therapy. Circulation 121:110-122
81. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ 2000 Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20:2670-2676
82. Otvos JD 2002 Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48:171-180 (Pubitemid 34272531)
83. Dattilo AM, Kris-Etherton PM 1992 Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 56:320-328
84. Sacks FM, Rudel LL, Conner A, Akeefe H, Kostner G, Baki T, Rothblat G, de la Llera-Moya M, Asztalos B, Perlman T, Zheng C, Alaupovic P, Maltais JA, Brewer HB 2009 Selective delipidation of plasmaHDLenhances reverse cholesterol transport in vivo. J Lipid Res 50:894-907
85. Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, Martin BD, Perlman TJ, Maltais JA, Weissman NJ, Fitzgerald PJ, Brewer Jr HB 2010 A first-in-man, randomized, placebo- controlled study to evaluate the safety and feasibility of autologous delipidated HDL plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 55:2727-2735
86. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, De- Maria AN 2004 Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071-1080 (Pubitemid 38541684)
87. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J 2007 Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297:1675-1682
88. Brewer Jr HB, Fairwell T, LaRue A, Ronan R, Houser A, Bronzert TJ 1978 The amino acid sequence of human apoA-I, an apolipoprotein isolated from high density lipoproteins. Biochem Biophys Res Commun 80:623-630 (Pubitemid 8275453)
89. Epand RM, Gawish A, Iqbal M, Gupta KB, Chen CH, Segrest JP, Anantharamaiah GM 1987 Studies of synthetic peptide analogs of the amphipathic helix. Effect of charge distribution, hydrophobicity, and secondary structure on lipid association and lecithin:cholesterol acyltransferase activation. J Biol Chem 262:9389-9396
90. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Navab M, Reddy ST, Buga GM, Fogelman AM 2009 Apolipoprotein A-I mimetic peptides. Curr Atheroscler Rep 11:52-57
91. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M, Anantharamaiah GM, Fogelman AM 2008 Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 49:2302-2311
92. Van Lenten BJ, Wagner AC, Navab M, Anantharamaiah GM, Hui EK, Nayak DP, Fogelman AM 2004 D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 110:3252-3258 (Pubitemid 39525074)
93. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, De- Groot BJ, Movva R, Navab M, Fogelman AM, Rader DJ 2008 Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 49:1344-1352
94. Sethi AA, Stonik JA, Thomas F, Demosky SJ, Amar M, Neufeld E, Brewer HB, Davidson WS, D'Souza W, Sviridov D, Remaley AT 2008 Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem 283:32273-32282
95. Sviridov D, Murphy A, Woolard K, Hoang A, Mukhamedova N 2008 High-density lipoprotein reduces the human monocyte inflammatory response through ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol 28:e-57:P170 (Abstract)
96. Akeefe H, Maltais JB, Murphy A, Chin-Dusting J, Dviridow D, Heather A, Liong E, Tan J, Rye K, Brewer HB 2008 An apo A-I mimetic peptide LSI-518P exhibits ABCA1-specific efflux and antiinflammatory properties. Arterioscler Thromb Vasc Biol 28:e-92:P322 (Abstract)
97. Bielicki JK, Zhang H, Azhar R, Johansson J, Azhar S 2008 A novel synthetic α-helix peptide that stimulates ABCA1 cholesterol efflux with high efficiency greatly reduces established atherosclerosis in hypercholesterolemic apolipoprotein E null mice. Arterioscler Thromb Vasc Biol 28:e-92:P326 (Abstract)
98. Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, Sirah W, Betteridge A, Reyes R, Yu Q, Kuznetsova O, Sisk CM, Pasternak RC, Paolini JF 2008 Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 62:1959-1970
99. Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, Mallick M, Sisk CM, Paolini JF, Mitchel Y 2009 Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 104:74-81
100. Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, Ishigami M, Sakai N, Kameda-Takemura K, Matsuzawa Y 1997 Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutations is not associated with longevity. Arterioscler Thromb Vasc Biol 17:1053-1059
101. Moriyama Y, Okamura T, Inazu A, Doi M, Iso H, Mouri Y, Ishikawa Y, Suzuki H, Iida M, Koizumi J, Mabuchi H, Komachi Y 1998 A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 27:659-667 (Pubitemid 28452494)
102. Hirano K, Yamashita S, Matsuzawa Y 2000 Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol 11: 589-596
103. Thuren T, Longcore A, Powell C, Strand J, Durham K, Shear C 2005 Torcetrapib combined with atorvastatin raises HDL-C, lowers LDL-C and is well tolerated: results from a phase 2 dose-ranging clinical trial. Circulation 112:II-179 (Abstract)
104. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Lasala GP, TuzcuEM 2007 Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356:1304-1316
105. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML 2007 Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356: 1620-1630 (Pubitemid 46631671)
106. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ 2007 Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370:153-160 (Pubitemid 47042895)
107. Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ 2008 Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 118:2515-2522
108. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators 2007 Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109-2122 (Pubitemid 350146106)
109. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker 3rd M, West SH, White V, Woltmann RF 2008 Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154:1465-1473
110. Stroes ES, Kastelein JJ, Bénardeau A, Kuhlmann O, Blum D, Campos LA, Clerc RG, Niesor EJ 2009 Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensinaldosterone system in rats. Br J Pharmacol 158:1763-1770
111. Stein EA, Stroes ES, Steiner G, Buckley BM, Capponi AM, Burgess T, Niesor EJ, Kallend D, Kastelein JJ 2009 Safety and tolerability of dalcetrapib. Am J Cardiol 104:82-91
112. Masson D 2009 Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis. Curr Opin Investig Drugs 10:980-987
113. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ 2002 Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT- 705, in humans: a randomized phase II dose-response study. Circulation 105:2159-2165 (Pubitemid 34517159)
114. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators 2009 Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 158:896-901.e3
115. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA 2007 Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 370:1907-1914 (Pubitemid 350192656)
116. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P 2010 Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 363:2406-2415
117. Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J, Krimbou L, Wong NC, Genest J 2010 RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 55:2580-2589